Lamb-Shaffer syndrome presenting as short stature with delays in motor and language acquisition: a case report and literature review
Received date: 2022-02-05
Online published: 2022-08-17
目的：分析1例以矮小伴语言运动发育迟缓为主要表现的Lamb-Shaffer综合征（Lamb-Shaffer syndrome,LAMSHF）患者的临床资料和基因检测结果,以提高临床医师对本病的认识。方法：分析本院收治的1例表现为严重身材矮小和语言运动发育迟缓的LAMSHF男性患儿,收集其临床资料,并抽取患儿及父母全血,提取基因组DNA进行全外显子测序及DNA Sanger测序。同时,在国内外数据库中检索相关文献,分析LAMSHF病例的临床特征、诊治方法及预后。结果：本例患儿9岁2个月,身高108.7 cm [-4.82个标准差（standard deviation,SD）],体重17.1 kg（<-2.1 SD）,体质量指数14.5 kg/m2（-1.1 SD）,大运动及语言发育延迟1年,实验室检查示胰岛素样生长因子水平为74 ng/mL（-2.14 SD）,生长激素激发试验提示非生长激素缺乏,其他检查无异常。全外显子测序提示,患儿第12号染色体p12.1到p11.1位置（p12.1s;p11.1）,存在至少10.4 Mb的拷贝数缺失,涉及SOX5等多个已知致病基因,发现该杂合变异来源于父源染色体,父母验证基因正常,提示该拷贝数变异为新发突变。遗传变异分类标准与指南指南评估该突变为可能致病[强致病证据（strong piece of evidence for pathogenicity,PS2）+中等致病证据（moderate piece of evidence for pathogenicity,PM1）],故诊断患儿为LAMSHF。收集分析11项研究共75例LAMSHF患者,LAMSHF的诊断依赖基因检测,且尚无明确的基因型-表型相关性,患者的智力障碍改善依赖于康复治疗。由于本病患者发生癫痫、眼征、肌张力减退风险较高,且有肿瘤倾向,预后不佳,对于矮小症状应避免使用生长激素。结论：LAMSHF的诊断依赖包括SOX5基因在内的基因检测。本例LAMSHF患儿携带目前已知的最大12p12.1缺失片段,且矮小程度最严重。临床上,对于合并智力异常的矮小症患儿,需进行SOX5突变及拷贝数变异筛查,同时治疗时应避免盲目使用生长激素带来的潜在危害。
关键词： 矮小症; 语言发育迟缓; 运动发育迟缓; Lamb-Shaffer综合征
张娟娟, 何亲羽, 杨媛艳, 董治亚, 肖园, 陈立芬, 张彩萍 . Lamb-Shaffer综合征表现为矮小症伴语言、运动发育迟缓一例及文献复习[J]. 诊断学理论与实践, 2022 , 21(03) : 336 -342 . DOI: 10.16150/j.1671-2870.2022.03.008
Objective: To analyze a case of Lamb-Shaffer syndrome(LAMSHF) with short stature and delayed language and motor development as the main manifestation,and summerize data of the disease in data bank for improving the understanding of this disease. Methods: A male child aged 9 year and 3 months with severe short stature and delayed language and motor development admitted to our hospital was analyzed. Their clinical data were collected, and the genomic DNA was extracted from whole blood of the children and their parents for whole exome sequencing and DNA Sanger sequencing verification. Meanwhile, relevant literature was reviewed to analyze the pathogenesis, clinical characteri-stics, diagnosis and therapy and prognosis of LAMSHF. Results: The height of the boy was 108.7 cm [-4.82 standard deviation (SD)], weight was 17.1 kg (<-2.1 SD), body mass index was 14.5 kg/m2 (-1.1 SD), and gross motor and language development 1-year delay. Laboratory test showed the insulin-like growth factor was 74 ng/mL (-2.14 SD), growth hormone challenge test suggested growth hormone and the remaining tests were all normal. Whole exome sequencing revealed that Seq[GRCh37]del(12)(p12.1s; p11.1) involved multiple known pathogenic genes including SOX5, with a copy number deletion of at least 10.4 Mb, and which were not detected before, so the copy number variant was a novel mutation. The mutation was assessed by ACMG guidelines as probable pathogenic (PS2+PM1). Therefore Lamb-Shaffer syndrome was diagnosed. Literature reviewing indicated that 11 LAMSHF-related studies included 1 domestic study and 10 foreign studies, with a total of 75 patients. The diagnosis of LAMSHF depended on genetic testing, and there is no clear genotype-phenotype correlation. The improvement of the patient's intellectual disability depended on rehabilitation treatment. Due to the high risk of epilepsy, ocular signs, and hypotonia in this disease, and the tendency to have tumors, growth hormone should be avoided for treatment of short stature. Patients with this disease currently had a poor prognosis. Conclusions: The boy with LAMSHF carried 12p12.1 deletion, which is the largest deletion and is never reported, presenting severe short stature. Short stature children with abnormal intelligence need to be screened for gene mutation and copy number variation of SOX5, and growth hormone therapy should be avoided due to potential risk of tumorigenesis.
| [1] | Zawerton A, Mignot C, Sigafoos A, et al. Widening of the genetic and clinical spectrum of Lamb-Shaffer syndrome, a neurodevelopmental disorder due to SOX5 haploinsufficiency[J]. Genet Med, 2020, 22(3):524-537. |
| [2] | 中华医学会儿科学分会内分泌遗传代谢学组. 矮身材儿童诊治指南[J]. 中华儿科杂志, 2008, 46(6):428-430. |
| [2] | Endocrine Genetics and Metabolism Group of Pediatrics Branch of Chinese Medical Association. Guidelines for the diagnosis and treatment of short stature children[J]. Chinese Journal of Pediatrics. 2008; 58(6):443-446. |
| [3] | Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5):405-524. |
| [4] | Schanze I, Schanze D, Bacino CA, et al. Haploinsufficiency of SOX5, a member of the SOX (SRY-related HMG-box) family of transcription factors is a cause of intellectual disability[J]. Eur J Med Genet, 2013, 56(2):108-113. |
| [5] | Lamb AN, Rosenfeld JA, Neill NJ, et al. Haploinsufficiency of SOX5 at 12p12.1 is associated with developmental delays with prominent language delay, behavior problems, and mild dysmorphic features[J]. Hum Mutat, 2012, 33(4):728-740. |
| [6] | Fukushi D, Yamada K, Suzuki K, et al. Clinical and genetic characterization of a patient with SOX5 haploinsufficiency caused by a de novo balanced reciprocal translocation[J]. Gene, 2018, 655:65-70. |
| [7] | Lee RW, Bodurtha J, Cohen J, et al. Deletion 12p12 involving SOX5 in two children with developmental delay and dysmorphic features[J]. Pediatr Neurol, 2013, 48(4):317-320. |
| [8] | Quintela I, Barros F, Lago-Leston R, et al. A maternally inherited 16p13.11-p12.3 duplication concomitant with a de novo SOX5 deletion in a male patient with global developmental delay, disruptive and obsessive behaviors and minor dysmorphic features[J]. Am J Med Genet A, 2015, 167(6):1315-1322. |
| [9] | Nesbitt A, Bhoj EJ, McDonald Gibson K, et al. Exome sequencing expands the mechanism of SOX5-associated intellectual disability: A case presentation with review of sox-related disorders[J]. Am J Med Genet A, 2015, 167A(11):2548-2554. |
| [10] | Zech M, Poustka K, Boesch S, et al. SOX5-Null Heterozygous Mutation in a Family with Adult-Onset Hyperkinesia and Behavioral Abnormalities[J]. Case Rep Genet, 2017, 2017:2721615. |
| [11] | Gkirgkinoudis A, Tatsi C, DeWard SJ, et al. A SOX5gene variant as a possible contributor to short stature[J]. Endocrinol Diabetes Metab Case Rep, 2020, 2020:20-0133. |
| [12] | Innella G, Greco D, Carli D, et al. Clinical spectrum and follow-up in six individuals with Lamb-Shaffer syndrome (SOX5)[J]. Am J Med Genet A, 2021, 185(2):608-613. |
| [13] | 曹井贺, 李建伟, 张玉芹, 等. 一例Lamb-Shaffer综合征患者的 SOX5基因变异分析[J]. 中华医学遗传学杂志, 2021, 38(8):765-767. |
| [13] | Cao JH, Li JW, Zhang YQ, et al. Variant analysis of SOX5 gene in a Lamb-Shaffer syndrome family[J]. Chinese Journal of Medical Genetics, 2021, 38(8):765-767. |
| [14] | Schepers GE, Teasdale RD, Koopman P. Twenty pairs of sox: extent, homology, and nomenclature of the mouse and human sox transcription factor gene families[J]. Dev Cell, 2002, 3(2):167-170. |
| [15] | Ikeda T, Zhang J, Chano T, et al. Identification and characterization of the human long form of Sox5 (L-SOX5) gene[J]. Gene, 2002, 298(1):59-68. |
| [16] | Kiselak EA, Shen X, Song J, et al. Transcriptional regulation of an axonemal central apparatus gene, sperm-associated antigen 6, by a SRY-related high mobility group transcription factor, S-SOX5[J]. J Biol Chem, 2010, 285(40):30496-30505. |
| [17] | Wunderle VM, Critcher R, Ashworth A, et al. Cloning and characterization of SOX5, a new member of the human SOX gene family[J]. Genomics, 1996, 36(2):354-358. |
| [18] | Besenbacher S, Sulem P, Helgason A, et al. Multi-nucleotide de novo Mutations in Humans[J]. PLoS Genet, 2016, 12(11):e1006315. |
| [19] | Lu HY, Cui YX, Shi YC, et al. A girl with distinctive features of borderline high blood pressure, short stature, characteristic brachydactyly, and 11.47 Mb deletion in 12p11.21-12p12.2 by oligonucleotide array CGH[J]. Am J Med Genet A, 2009, 149A(10):2321-2323. |
| [20] | Klopocki E, Hennig BP, Dathe K, et al. Deletion and point mutations of PTHLH cause brachydactyly type E[J]. Am J Hum Genet, 2010, 86(3):434-439. |
| [21] | Martinez-Morales PL, Quiroga AC, Barbas JA, et al. SOX5 5 controls cell cycle progression in neural progenitors by interfering with the WNT-beta-catenin pathway[J]. EMBO Rep, 2010, 11(6):466-472. |
| [22] | Shiseki M, Masuda A, Yoshinaga K, et al. Identification of the SOX5 gene as a novel IGH-involved translocation partner in BCL2-negative follicular lymphoma with t(12;14)(p12.2;q32)[J]. Int J Hematol, 2015, 102(5):633-638. |
| [23] | Seifert MB, Olesen MS, Christophersen IE, et al. Genetic variants on chromosomes 7p31 and 12p12 are associated with abnormal atrial electrical activation in patients with early-onset lone atrial fibrillation[J]. Ann Noninvasive Electrocardiol, 2019, 24(6):e12661. |
| [24] | Zhang L, Xu X, Chen Y, et al. Mapping of developmental dysplasia of the hip to two novel regions at 8q23-q24 and 12p12[J]. Exp Ther Med, 2020, 19(4):2799-2803. |
| [25] | Perdomo S, Anantharaman D, Foll M, et al. Genomic analysis of head and neck cancer cases from two high incidence regions[J]. PLoS One, 2018, 13(1):e0191701. |
| [26] | Grant TJ, Mehta AK, Gupta A, et al. STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines[J]. Oncotarget, 2017, 8(45):78556-78572. |
| [27] | Huang H, Shen H, Wang Y, et al. LOH12CR1 is a novel tumor suppressor inhibiting tumor growth through dere-gulation of G1/S checkpoint in human colorectal carcinoma[J]. Curr Mol Med, 2018, 18(1):25-35. |
| [28] | Yeh CN, Chen MH, Chang YC, et al. Over-expression of TNNI3K is associated with early-stage carcinogenesis of cholangiocarcinoma[J]. Mol Carcinog, 2019, 58(2):270-278. |
/
| 〈 |
|
〉 |
